Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
41 hedge funds and large institutions have $86.5M invested in Agile Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 17 closing their positions.
18% more capital invested
Capital invested by funds: $73.6M → $86.5M (+$12.9M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
15% less funds holding
Funds holding: 48 → 41 (-7)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$2.7M |
| 2 |
NIM
Needham Investment Management
New York
|
+$706K |
| 3 |
Millennium Management
New York
|
+$450K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$284K |
| 5 |
Goldman Sachs
New York
|
+$284K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.99M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$927K |
| 3 |
State Street
Boston,
Massachusetts
|
-$512K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$415K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$263K |
AGRX Hedge Fund Activity: Q2 2017 in Review
41 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2017, worth a combined $86.5M — up 18% from $73.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of AGRX and 10 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was Franklin Resources, adding an estimated $2.7M. The largest seller was BlackRock, cutting an estimated $1.99M.
- 41 institutional investors held Agile Therapeutics (AGRX) as of Q2 2017, down from 48 in Q1 2017.
- Funds reported $86.5M of Agile Therapeutics stock for Q2 2017, up 18% quarter-over-quarter.
- 10 funds opened new Agile Therapeutics positions in Q2 2017 and 17 closed out, a net change of -7 holders.
- The largest Agile Therapeutics buyer in Q2 2017 was Franklin Resources, an estimated $2.7M added.
- The largest Agile Therapeutics seller in Q2 2017 was BlackRock, an estimated $1.99M sold.
Based on aggregated 13F filings for Q2 2017.